Trial Profile
26-week, international multicenter, open, non-randomized phase III clinical trial for evaluation of efficacy and safety of insulin glulysine (HME1964) injected subcutaneously in subjects with type 1 diabetes mellitus also using insulin glargine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2010
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 26 Oct 2007 New trial record.